Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josephine Tabea Tauer

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Hematologic Malignancy Reports|March 8, 2012
Management of chronic myeloid leukemia in childhoodMeinolf Suttorp, Louise Eckardt, Josephine Tabea Tauer, et al.
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|November 30, 2010
Investigations of Platelet Function in Whole Blood with BAPA as AnticoagulantJosephine Tabea Tauer, Judith Lohse, Silvia König, et al.
Molecular Medicine Reports|December 16, 2014
Inhibitory effects of imatinib on vitamin D₃ synthesis in human keratinocytesLysann Michaela Mehlig, Claudia Garve, Josephine Tabea Tauer, et al.
Medical Science Monitor Basic Research|November 5, 2013
Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growthJosephine Tabea Tauer, Lorenz C Hofbauer, Rolang Jung, et al.
Molecular Medicine Reports|November 9, 2017
Off‑target effect of imatinib and nilotinib on human vitamin D3 metabolismLysann Kroschwald, Meinolf Suttorp, Josephine Tabea Tauer, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|December 1, 2012
Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatmentBernadette Anna Sophia Jaeger, Josephine Tabea Tauer, Anna Ulmer, et al.
Oncology Letters|August 20, 2019
Imatinib mesylate and nilotinib decrease synthesis of bone matrix <i>in vitro</i>Lysann Michaela Kroschwald, Josephine Tabea Tauer, Sonja Ingrid Kroschwald, et al.
Oncology Letters|June 22, 2026
Erratum: [Corrigendum] Imatinib mesylate and nilotinib decrease synthesis of bone matrix <i>in vitro</i>Lysann Michaela Kroschwald, Josephine Tabea Tauer, Sonja Ingrid Kroschwald, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Hematologic Malignancy Reports|March 8, 2012
Management of chronic myeloid leukemia in childhoodMeinolf Suttorp, Louise Eckardt, Josephine Tabea Tauer, et al.
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|November 30, 2010
Investigations of Platelet Function in Whole Blood with BAPA as AnticoagulantJosephine Tabea Tauer, Judith Lohse, Silvia König, et al.
Molecular Medicine Reports|December 16, 2014
Inhibitory effects of imatinib on vitamin D₃ synthesis in human keratinocytesLysann Michaela Mehlig, Claudia Garve, Josephine Tabea Tauer, et al.
Medical Science Monitor Basic Research|November 5, 2013
Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growthJosephine Tabea Tauer, Lorenz C Hofbauer, Rolang Jung, et al.
Molecular Medicine Reports|November 9, 2017
Off‑target effect of imatinib and nilotinib on human vitamin D3 metabolismLysann Kroschwald, Meinolf Suttorp, Josephine Tabea Tauer, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|December 1, 2012
Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatmentBernadette Anna Sophia Jaeger, Josephine Tabea Tauer, Anna Ulmer, et al.
Oncology Letters|August 20, 2019
Imatinib mesylate and nilotinib decrease synthesis of bone matrix <i>in vitro</i>Lysann Michaela Kroschwald, Josephine Tabea Tauer, Sonja Ingrid Kroschwald, et al.
Oncology Letters|June 22, 2026
Erratum: [Corrigendum] Imatinib mesylate and nilotinib decrease synthesis of bone matrix <i>in vitro</i>Lysann Michaela Kroschwald, Josephine Tabea Tauer, Sonja Ingrid Kroschwald, et al.
Pageof 1